Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Alpine Immune Sciences, Inc. by Year
Alpine Immune Sciences, Inc. (CIK 0001626199, acquired May 2024 for povetacicept, $4.9B) — Pre-acquisition R&D expense ($M) ($M)
Vertex Pharmaceuticals Alpine Immune Sciences, Inc.: $80.9M in FY2023, up 15.2% from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
Source: SEC Filing ↗
Reported in SEC XBRL (CIK 0001626199 Alpine Immune Sciences, FY2018–FY2024Q1 pre-acquisition).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Alpine Immune Sciences, Inc. (CIK 0001626199, acquired May 2024 for povetacicept, $4.9B) — Pre-acquisition R&D expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 80.9 | +15.2% | SEC Filing ↗ |
| FY2022 | Dec 31, 2022 | 70.2 | +19.6% | SEC Filing ↗ |
| FY2021 | Dec 31, 2021 | 58.7 | +116.1% | SEC Filing ↗ |
| FY2020 | Dec 31, 2020 | 27.2 | -24.2% | SEC Filing ↗ |
| FY2019 | Dec 31, 2019 | 35.9 | +23.7% | SEC Filing ↗ |
| FY2018 | Dec 31, 2018 | 29.0 | – | SEC Filing ↗ |
Breakdown
What makes up alpine Immune Sciences, Inc.
- Alpine Immune Sciences — Collaboration revenue ($M)58.9 · FY2023
- Alpine Immune Sciences — General and administrative expense ($M)22.2 · FY2023
- Alpine Immune Sciences — Total operating expenses ($M)103 · FY2023
- Alpine Immune Sciences — Operating income (loss) ($M)-44.3 · FY2023
- Alpine Immune Sciences — Net income (loss) ($M)-32.2 · FY2023
- Alpine Immune Sciences — Stock-based compensation expense ($M)10.6 · FY2023
- Alpine Immune Sciences — Cash and cash equivalents ($M)43.9 · FY2023
- Alpine Immune Sciences — Marketable securities ($M)283 · FY2023
- Alpine Immune Sciences — Total assets ($M)380 · FY2023
- Alpine Immune Sciences — Total liabilities ($M)51.9 · FY2023
- Alpine Immune Sciences — Stockholders' equity ($M)328 · FY2023
Cite this data
StockData. (2026). Vertex Pharmaceuticals Alpine Immune Sciences, Inc. ($M), annual FY2018–FY2023 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/alpine-rd-exp
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.